

Protocol for Respiratory Syncytial Virus (RSV) Vaccine

1. What's New

- A. In September of 2025, the West Coast Health Alliance (WCHA) issued immunization recommendations for the 2025-2026 respiratory virus season. These recommendations were informed by trusted national medical organizations, including [American Academy of Pediatrics](#) (AAP), the [American College of Obstetricians and Gynecologists](#) (ACOG), and the [American Academy of Family Physicians](#) (AAFP). The WCHA believes that all recommended immunizations should be accessible to the people of our states.
- B. The American Academy of Pediatrics (AAP) is scheduled to release its new recommendations for respiratory vaccines between early August and early September of 2026, starting with influenza and followed by respiratory syncytial virus (RSV) and COVID-19. Furthermore, seasonal respiratory updates from the American Academy of Family Physicians (AAFP) typically align closely with this late summer and early fall rollout from the AAP. Given the meeting schedules of these primary recommending bodies, we anticipate that the West Coast Health Alliance (WCHA) will not meet before late September of 2026.

2. Immunization Protocol

- A. Administer a single lifetime dose, IM, RSV vaccine to all adults ages 75 years and older.
- B. Administer a single lifetime dose, IM, RSV vaccine to persons ages 50 through 74 years of age if they are at increased risk of severe RSV disease, as described in Section 4.
- C. Administer a single lifetime dose, IM, RSV vaccine to pregnant patients at 32-36 weeks gestational age.
- D. RSV vaccine may be given with all ACIP- and WCHA-recommended adult vaccinations, including COVID-19 vaccines.

3. Vaccine Schedule ¹

	RSV immunization
Pregnancy	32 through 36 weeks gestational age ⁱ
Adults	All ≥ 75 years ⁱⁱ All 50 through 74 years with risk factors ^{ii, iii}

ⁱ Either immunization with nirsevimab/clesrovimab or maternal RSV vaccination is indicated to protect infants from severe RSV infection.

ⁱⁱ Adult RSV immunization recommendations are currently for a single lifetime dose. Those who have previously received a dose do not need a second dose.

ⁱⁱⁱ See Section 4 for additional information on risk factors for severe RSV disease in adults 50-74 years.

4. Additional Considerations for Use

- A. For additional information on risk factors for severe RSV disease in adults 50 through 74 years of age, see: <https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html>.

5. Pregnancy and Lactation ²⁻⁴

- A. It is unknown if RSV vaccines are excreted in human milk.
- B. See current prescribing information additional considerations regarding pregnancy and lactation.

Protocol for Respiratory Syncytial Virus (RSV) Vaccine

6. Warnings and Precautions ²⁻⁴

- A. Individuals with acute, moderate, or severe illness with or without fever should delay immunization until symptoms have improved.
- B. Individuals with an immunocompromising condition may experience a diminished immune response to the vaccine.
- C. See current prescribing information for more details about warnings, precautions, formulation, and contents.

7. Contraindications ²⁻⁴

- A. Severe allergic reaction (e.g., anaphylaxis) to a previous dose or to any vaccine component.
- B. See current prescribing information for details about contraindications.

8. Storage and Handling ²⁻⁴

- A. Store medications according to [OAR 855-041-1036](#).
- B. See current prescribing information for additional details about storage and handling.

9. References

1. West Coast Health Alliance 2025-2026 Recommendations for Respiratory Vaccines. Available at: <https://www.oregon.gov/oha/PH/PreventionWellness/VaccinesImmunization/GETTINGIMMUNIZED/Documents/2025-26-Respiratory-Virus-Vaccine-Recommendations.pdf>
2. Abrysvo™. [Package insert]. October 2023. <https://www.fda.gov/media/168889/download>
3. Arexvy™. [Package insert]. June 2024. <https://www.fda.gov/media/167805/download?attachment>
4. mRESVIA®. [Package insert]. October 2024. <https://www.fda.gov/media/179005/download?attachment>